Tags : regains

Reata Regains Exclusive Worldwide Rights of its Nrf2 Activator Product

Shots: AbbVie to receive $330M in cash primarily for bardoxolone, $75M up front in 2019 and the remaining value payable in installments in Q2 and Q4 2020 plus royalties on WW sales of omaveloxolone and certain next-generation Nrf2 activators Reata reacquires WW rights to develop, manufacture and commercialize bardoxolone methyl (ex- Asian markets), omaveloxolone and […]Read More